logo
Twitter
Discord
Email
logo
Amarin Corporation plc

Amarin Corporation plc

NASDAQ•AMRN
CEO: Mr. Aaron D. Berg
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1993-04-01
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Contact Information
Iconic Offices, The Greenway, Block C Ardilaun Court St Stephens Green, Dublin, 112-114, Ireland
353-0-166-99020
www.amarincorp.com
Market Cap
$336.30M
P/E (TTM)
-78.4
37
Dividend Yield
--
52W High
$20.90
52W Low
$7.00
52W Range
67%
Rank57Top 83.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$48.56M+14.80%
4-Quarter Trend

EPS

-$0.02-67.27%
4-Quarter Trend

FCF

-$12.76M+424.21%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Q3 Net Loss Significantly Narrowed Q3 Net loss improved to $(7.7)M USD from $(25.1)M USD year ago; Q3 total revenue grew 17% to $49.7M USD.
Licensing Revenue Boosts 9M Results Nine months licensing revenue increased 30% to $28.2M USD, driven by $25.0M upfront payment from Recordati deal.
Operating Cash Flow Improved Net cash used in operating activities decreased $9.2M for nine months, ending at $(8.5)M used cash flow.
Restructuring Costs Recognized Recognized $32.2M restructuring expense for nine months related to Global Restructuring Plan following European licensing deal.

Risk Factors

U.S. Market Share Erosion Overall icosapent ethyl market share fell to 45% from 55% year-to-date; branded prescriptions decreased 17%.
European Partnership Dependency Revenue hinges on Recordati successfully commercializing VAZKEPA across 59 European countries under new agreement.
Nasdaq Listing Compliance Risk Received deficiency notice; must maintain $1.00 minimum bid price to avoid potential delisting of American Depositary Shares.
Inventory Levels Remain High Total inventory stands at $193.8M USD as of September 30, 2025; 49% is approved only for North America use.

Outlook

European Restructuring Savings Expected Global Restructuring Plan anticipates annual cost savings of approximately $70.0M USD following the Recordati agreement execution.
Liquidity Supports Operations Aggregate liquidity of $286.6M USD, including cash and short-term investments, supports projected operations for over one year.
Maintain U.S. Market Leadership Plan to competitively manage U.S. market leadership while driving expanded access and patient uptake globally in 2025.
R&D Investment Flexibility Investment priorities are continuously evaluated and subject to adjustment based on generic competition and reimbursement timing.

Peer Comparison

Revenue (TTM)

Amarin Corporation plcAMRN
$225.62M
-6.7%
Cellectis S.A.CLLS
$75.27M
+158.9%
Autolus Therapeutics plcAUTL
$51.13M
+330.9%

Gross Margin (Latest Quarter)

Korro Bio, Inc.KRRO
100.0%
+0.0pp
Lineage Cell Therapeutics, Inc.LCTX
99.9%
+0.9pp
Cellectis S.A.CLLS
93.3%
+10.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RAPT$953.06M-14.7-61.8%1.6%
DBVT$587.04M-3.9-295.2%0.0%
DSGN$579.89M-8.6-30.6%0.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-8.0%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 11, 2026
|
EPS:-$0.85
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 29, 2025|
    Revenue: $48.56M+14.8%
    |
    EPS: $-0.02-67.3%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 30, 2025|
    Revenue: $72.74M+7.7%
    |
    EPS: $-0.03-910.8%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $42.02M-25.6%
    |
    EPS: $-0.80+3192.2%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 12, 2025|
    Revenue: $228.61M-25.5%
    |
    EPS: $-0.20-33.3%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 30, 2024|
    Revenue: $42.30M-36.0%
    |
    EPS: $-0.06+29.2%
    Meet

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 31, 2024|
    Revenue: $67.57M-15.7%
    |
    EPS: $0.00-108.6%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 1, 2024|
    Revenue: $56.49M-34.3%
    |
    EPS: $-0.02-40.0%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 29, 2024|
    Revenue: $306.91M-16.9%
    |
    EPS: $-0.15+42.3%
    Beat